Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

• ClinicalTrials.gov Identifier: NCT02087241
• Recruitment Status: Terminated
• First Posted: March 14, 2014
• Results First Posted: March 29, 2017
• Last Update Posted: March 29, 2017
• Sponsor: AstraZeneca
• Information provided by (Responsible Party): AstraZeneca

Study Description

Brief Summary:

The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.

Condition or disease	Intervention/treatment	Phase
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer	Drug: AZD1775; Drug: AZD1775 Matching Placebo; Drug: pemetrexed; Drug: carboplatin	Phase 2

Detailed Description:

This is a randomised, phase II trial comparing AZD1775 plus pemetrexed and carboplatin followed by maintenance AZD1775 and pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed in patients with previously untreated metastatic non-squamous NSCLC with TP53 mutations. The primary endpoint of the trial is assessment of progression-free survival (PFS).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 22 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer
• Study Start Date: March 2014
• Actual Primary Completion Date: June 2015
• Actual Study Completion Date: June 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: AZD1775 + carboplatin + pemetrexed; Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.	Drug: AZD1775; AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies; Other Name: MK-1775; Drug: pemetrexed; This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.; Drug: carboplatin; This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
Experimental: Placebo + carboplatin + pemetrexed; Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.	Drug: AZD1775 Matching Placebo; AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies; Drug: pemetrexed; This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.; Drug: carboplatin; This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival [ Time Frame: 6 months ]
   Progression free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.

Secondary Outcome Measures :

1. Assess the Objective Response Rates in Each Arm [ Time Frame: Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days) ]
   The objective response rate is defined as the number of the subjects with a confirmed best overall response of CR or PR divided by the number of subjects in the Full Analysis Set (FAS) for whom measureable disease is present at baseline
2. Assess the Disease Control Rate in Each Treatment Arm [ Time Frame: Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days) ]
   the disease control rate is defined as the percentage of FAS subjects with a best overall response of CR, PR or SD).
3. Assess the Duration of Response in Each Treatment Arm [ Time Frame: Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days) ]
   Duration of response is defined as the time from the date of first documented response until the date of documented progression or any cause death.
4. Assess Overall Survival in Each Treatment Arm [ Time Frame: Up to a maximum of 4 treatment cycles (treatment cycles will be repeated every 21 days) ]
   Overall survival is defined as the time from the date of randomization until death due to any cause.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• Provision of informed consent prior to any study specific procedures
• Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).
• No prior chemotherapy for locally advanced or metastatic disease
• Subjects with a known EGFR mutation must have received previous treatment with an EGFR tyrosine kinase inhibitor; and subjects with a known ALK translocation must have received previous treatment with an ALK inhibitor.
• No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow area.
• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
• Mandatory availability of tumour tissue (archival or fresh if archival is not available) for TP53 determination.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
• Absolute neutrophil count (ANC) ≥1500/μL
• Hemoglobin (Hgb) ≥10 g/dL
• Platelets ≥100,000/μL
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ≤3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases
• Total bilirubin ≤1.5 x ULN, unless secondary to Gilbert's disease
• Serum creatinine ≤1.5 x ULN and a calculate creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method
• Ability to swallow oral medication
• Fertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops
• Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of study treatment
• Predicted life expectancy ≥12 weeks
• Must be ≥18 years of age
• Willingness and ability to comply with study and follow-up procedures
• Ability to understand the nature of this trial and give written informed consent Exclusion criteria
• Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of AZD1775
• Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures ≤7 days
• Known central nervous system (CNS) disease
• Subject has had prescription or non-prescription drugs or other products (i.e. grapefruit juice) known to be sensitive CYP3A4 substrates
• Any known hypersensitivity or contraindication to the components of study treatment
• Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association ([NYHA] Appendix G) ≥ Class 2
• Corrected QT interval (QTc) >470 msec (as calculated by Fridericia correction formula) at study entry or congenital long QT syndrome.
• Pregnant or lactating
• Any serious, active underlying medical condition that would impair the ability of the subjects to receive study treatment
• Unable or unwilling to take folic acid or vitamin B12
• Presence of other active cancers, or history of treatment for invasive cancer ≤3 years
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Contacts and Locations

Locations

United States, Colorado

Research Site

Englewood, Colorado, United States

United States, Florida

Research Site

Fort Myers, Florida, United States

Research Site

Orlando, Florida, United States

United States, Illinois

Research Site

Peoria, Illinois, United States

United States, Indiana

Research Site

Fort Wayne, Indiana, United States

United States, Kansas

Research Site

Wichita, Kansas, United States

United States, Ohio

Research Site

Cincinnati, Ohio, United States

United States, Tennessee

Research Site

Nashville, Tennessee, United States

Sponsors and Collaborators

AstraZeneca

Investigators

• Principal Investigator: David R Spigel, MD; SCRI Development Innovations, LLC

More Information

• Responsible Party: AstraZeneca
• ClinicalTrials.gov Identifier: NCT02087241
• Other Study ID Numbers: D6011C00002
• First Posted: March 14, 2014
• Results First Posted: March 29, 2017
• Last Update Posted: March 29, 2017
• Last Verified: February 2017

Keywords provided by AstraZeneca:

Stage IV Lung Cancer

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carboplatin; Pemetrexed; Adavosertib; Antineoplastic Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors